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Abstract  
 
Vascular endothelial growth factor A (VEGF-A), is considered one of the most important 
factors in tumor angiogenesis, and consequently a number of therapeutics have been 
developed to inhibit VEGF signalling. Therapeutic strategies to target brain malignancies, 
both primary brain tumors, particularly in pediatric patients, and metastases, are lacking, but 
targeting angiogenesis may be a promising approach. 
Multiparametric MRI was used to investigate the response of orthotopic SF188luc pediatric 
glioblastoma xenografts to small molecule pan-VEGFR inhibitor cediranib; and the effects of 
both cediranib and cross-reactive human/mouse anti-VEGF-A antibody B20-4.1.1 in 
intracranial MDA-MB-231 LM2-4 breast cancer xenografts over 48 hours. 
All therapeutic regimens resulted in significant tumor growth delay. In cediranib-treated 
SF188luc tumors this was associated with lower Ktrans (compound biomarker of perfusion and 
vascular permeability) than in vehicle-treated controls. Cediranib also induced significant 
reductions in both Ktrans and apparent diffusion coefficient (ADC) in MDA-MB-231 LM2-4 
tumors associated with decreased histologically-assessed perfusion. B20-4.1.1 treatment 
resulted in decreased Ktrans but in the absence of a change in perfusion; a non-significant 
reduction in vascular permeability, assessed by Evans blue extravasation, was observed in 
treated tumors. The imaging responses of intracranial MDA-MB-231 LM2-4 tumors to 
VEGF/VEGFR pathway inhibitors with differing mechanisms of action are subtly different. 
We show that VEGF pathway blockade resulted in tumor growth retardation and inhibition of 
tumor vasculature in preclinical models of pediatric glioblastoma and breast cancer brain 
metastases, suggesting that multiparametric MRI can provide a powerful adjunct to accelerate 
the development of antiangiogenic therapies for use in these patient populations. 
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Abbreviations  
 
ADC Apparent diffusion coefficient 
DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging 
DW-MRI Diffusion-weighted magnetic resonance imaging 
fBV  Fractional blood volume 
H&E Hematoxylin and eosin 
IAUGC60  Initial area under the gadolinium concentration curve at 60 seconds 
MGE  Multi gradient-recalled echo 
MRI Magnetic resonance imaging 
pHGG  Pediatric high grade glioma 
TNBC Triple negative breast carcinoma 
VEGF  Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
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Introduction 
 
Angiogenesis, the development of new blood vessels in order to provide a nutritive blood 
supply, is considered essential for expansive tumor growth in the brain [1]. Stimulated by the 
secretion of numerous growth factors by tumor cells, endothelial cells and tumor-associated 
macrophages [2], angiogenesis in tumors results in structurally irregular vessels that are more 
tortuous, fragile, dilated and hyper-permeable than normal blood vessels [3]. Vascular 
endothelial growth factor A (VEGF-A) is considered one of the most important factors in 
tumor angiogenesis [4]. Consequently a number of therapeutic strategies, including small 
molecules that inhibit VEGF receptor tyrosine kinase activity (e.g. cediranib) and 
neutralizing antibodies that specifically bind VEGF-A (e.g. bevacizumab), have been 
developed [5, 6]. 
Pediatric high grade gliomas (pHGG) have a very poor clinical outcome, with a median 
overall survival of 9-18 months [7]; effective treatment strategies are urgently required for 
these patients. Although it is now clearly recognized that pHGGs have distinct underlying 
biology compared with histologically similar tumors arising in older adults [8, 9], many key 
features and pathways are commonly dysregulated. Microvascular endothelial cell 
proliferation is a key feature of grade IV glioma, glioblastoma, in the WHO classification 
system, which, along with evidence of necrosis, distinguishes them from grade III tumors, 
which show evidence of anaplasia and have a high mitotic index. Consequently, with the 
exception of pilocytic astrocytoma, a highly vascular grade I astrocytoma, tumor vascularity 
is associated with higher grade [10]. VEGF-A is highly expressed in pediatric brain tumors 
and is thought to be partly responsible for the loss of blood brain barrier integrity during 
tumor growth [11]. 
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Brain metastases occur in approximately 30% of patients with breast cancer and are an 
important cause of cancer morbidity and mortality [12]. Highly proliferative breast tumors, 
such as those negative for the estrogen, progesterone, and Her2/neu receptors, have enhanced 
angiogenesis that supports rapid growth and early metastasis, and express high levels of 
VEGF [13]. Therefore, patients with breast tumors expressing high levels of VEGF may be at 
a higher risk of developing metastases in the brain, hence antiangiogenic agents may also 
represent promising agents for the treatment of such tumors.  
Magnetic resonance imaging (MRI) enables the visualization of detailed anatomical features 
with high resolution due to its exquisite soft tissue image contrast, and is the gold standard 
non-invasive method for the diagnosis, surgical planning and monitoring of brain tumors 
[14]. However, imaging cannot at present replace biopsy for the accurate histological grading 
of tumors. Furthermore, advances in functional MRI can provide quantitative biomarkers that 
inform on biologically relevant structure-function relationships, their heterogeneous 
distribution, and treatment response/resistance in brain tumors [15, 16]. The Response 
Assessment in Neuro-Oncology (RANO) guidelines, based on evaluations of adult HGGs, 
aim to provide more specific and standardized imaging protocols incorporating assessment of 
non-enhancing components of tumors [17]. The Response Assessment in Pediatric Neuro-
Oncology (RAPNO) working group was subsequently established to address the unique 
challenges associated with pediatric neuro-oncology, for example the more heterogeneous 
group of diseases arising  in children, with a higher prevalence of low grade, infratentorial 
and brainstem tumors, and the relatively small numbers of cases available for clinical trials 
[18, 19]. 
In this study, we undertook a multiparametric MRI approach to investigate the response of 
orthotopic SF188 pediatric glioblastoma xenografts, and highly malignant MDA-MB-231 
LM2-4 human triple negative breast carcinoma (TNBC) xenografts implanted in the brain, to 
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cediranib, a small molecule pan-VEGFR inhibitor. This approach was also used to assess the 
effect of B20-4.1.1, a cross-reactive human/mouse derivative of bevacizumab, on intracranial 
MDA-MB-231 LM2-4 xenografts.   
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Materials and Methods  
 
Cell Culture 
SF188 pediatric glioblastoma cells were maintained in Dulbecco’s modified Eagle’s medium 
Hams F12 mixture (Sigma-Aldrich, Gillingham, UK) supplemented with 10% (v/v) fetal 
bovine serum (Invitrogen, Life Technologies, Paisley, UK) [20]. SF188 cells were engineered 
to stably express luciferase by transduction with the luc-2 gene (cloned from pGL4.10[luc2] 
(Promega, Madison, MI)) cloned into pCDH-CMV-CMS-EFI-hygro, a HIV lentiviral-based 
vector (System Biosciences, Mountain View, CA) and enriched for in vivo tumorigenicity via 
four sequential intracranial passages (SF188luc). Luciferase-expressing MDA-MB-231 LM2-4 
highly malignant human TNBC cells isolated from a lung metastasis [21] (provided by Dr. R. 
Kerbel, University of Toronto, Canada) were maintained in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Life Technologies) supplemented with 10% (v/v) fetal bovine serum. 
Both cell lines were authenticated by short tandem repeat (STR) profiling and tested negative 
for mycoplasma infection at the time of tumor implantation. 
 
Tumor Implantation 
All experiments were performed in accordance with the local Animal Welfare and Ethical 
Review Board, the UK Home Office Animals (Scientific Procedures) Act 1986, the United 
Kingdom National Cancer Research Institute guidelines for the welfare of animals in cancer 
research [22] and the ARRIVE (animal research: reporting in vivo experiments) guidelines 
[23].  
SF188luc (2x105) or MDA-MB-231 LM2-4 (5x103) cells were implanted supratentorially in 
the brains of 6 week old female athymic (NCr-Foxn1nu) mice (Charles River Ltd, Margate, 
UK), as previously described [24]. 
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Bioluminescence Imaging 
Tumor establishment and growth was monitored using a Xenogen IVIS® 200 system coupled 
with LivingImage software (Caliper Life Sciences, Runcorn, UK). Luciferin (150mg/kg, 
Caliper Life Sciences) was administered intraperitoneally 10 minutes before imaging. Total 
photon flux was established for automatically drawn ROIs at a constant threshold. A 
bioluminescence signal that represented a tumor volume of approximately 25mm3 had 
previously been established for each cell line; once this signal was reached animals were 
enrolled in MRI experiments. This starting volume was chosen to provide an experimental 
timeframe with minimal risk of mice developing adverse neurological symptoms prior to 
study end. 
 
MRI and Drug Treatment Schedules 
Tumor-bearing mice were randomized prior to MRI into control and treatment cohorts as 
follows:  
SF188luc 
i. MRI prior to and after 48h treatment with 6mg/kg cediranib (AZD2171, AstraZeneca) 
(n=6) or vehicle (1% polysorbate-80 in water) (n=5) daily. 3 oral doses were given over 
48h: i) following recovery from anesthesia for pre-treatment imaging, ii) 24h later, iii) a 
further 24h later immediately prior to post-treatment imaging.  
MDA-MB-231 LM2-4  
i. MRI prior to and after 48h treatment with either 6mg/kg cediranib (n=6) or vehicle 
(n=5), as described above. 
ii. MRI prior to and 48h after a single intraperitoneal 10mg/kg dose of B20-4.1.1 
(Genentech) (n=7) or an isotype-matched control antibody (anti-Ragweed:1428) (n=6). 
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Treatment and imaging regimens are depicted in supplementary Figure S1 with cohort sizes, 
time from tumor implantation to study start and mean pre-treatment tumor volume. 
 
Magnetic Resonance Imaging (MRI) 
Anesthesia was induced with a 10ml/kg intraperitoneal injection of fentanyl citrate 
(0.315mg/ml) plus fluanisone (10mg/ml (Hypnorm; Janssen Pharmaceutical Ltd. High 
Wycombe, UK)), midazolam (5mg/ml (Hypnovel; Roche, Burgess Hill, UK)), and sterile 
water (1:1:2). A lateral tail vein was cannulated with a 27G butterfly catheter (Venisystems, 
Hospira, Royal Leamington Spa, UK) to enable the remote administration of gadopentetate 
dimeglumine (Gd-DTPA, Magnevist™; Schering, Berlin, Germany) or ultrasmall 
paramagnetic iron oxide (USPIO) particles (P904; Guerbet, Villepinte, France). Anesthetized 
mice were then positioned prone in a 3cm birdcage coil within a 7T Bruker horizontal bore 
microimaging system (Ettlingen, Germany). Core body temperature was maintained by warm 
air blown through the magnet bore. All images were acquired over a 2.5cm x 2.5cm field of 
view. 
 
Anatomical T2-weighted, Diffusion-Weighted and Dynamic Contrast-Enhanced MRI  
Magnetic field homogeneity was optimized by shimming over the entire brain using an 
automated shimming routine (FASTmap). A rapid acquisition with relaxation enhancement 
(RARE) T2-weighted sequence (repetition time (TR)=4500ms, effective echo time 
(TEeff)=36ms, 4 averages, RARE factor=8, 256×256 matrix, 20×1mm thick contiguous axial 
slices) was used for localization of the tumor and measurement of tumor volume. Diffusion-
weighted (DW) images were then acquired using an echo-planar imaging (EPI) sequence 
(TR=1500ms, TE=32ms, 10 b-values; b=0, 30, 60, 100, 150, 200, 300, 500, 750, 1000s/mm2, 
4 averages, 128×128 matrix, 3x1mm thick axial slices through the tumor). 
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Dynamic contrast-enhanced (DCE) MRI data were acquired using an inversion recovery (IR) 
true fast imaging with steady-state precession (trueFISP) sequence with one baseline scan 
(TE=1.2ms, TR=2.4ms, scan TR=10s, 50 inversion times spaced 29ms apart (TI=25-1451ms), 
8 averages, flip angle=60°, matrix=128x96, 1x1mm thick slice) and 60 dynamic scans 
(TE=1.2ms, TR=2.4ms, scan TR=10s, 8 inversion times spaced 116ms apart (TI=109-924ms), 
1 average, flip angle=60°, temporal resolution=20s). A bolus of Gd-DTPA (0.1mmol/kg 
Magnevist™ i.v., 2ml/kg 50mM solution) was administered at 2ml/minute using a power 
injector 3 minutes after the start of the dynamic sequence [25]. 
This imaging protocol was performed in mice bearing SF188luc or MDA-MB-231 tumors at 
baseline and after 48h treatment with 6mg/kg cediranib, or vehicle, given orally daily, and 
mice bearing MDA-MB-231 LM2-4 tumors before and 48h following a single intraperitoneal 
dose of 10mg/kg B20-4.1.1 or isotype control Ragweed:1428 (see supplementary Figure S1). 
 
Susceptibility Contrast MRI 
Magnetic field homogeneity was optimized and T2-weighted images were acquired. Multi 
gradient-recalled echo (MGE) images (TR=1000ms, TE=6.2-31.1ms, 8 echoes, 2 averages, 
256x256 matrix, 3x1mm thick slices) were acquired for quantification of relaxation rate R2*. 
USPIO particles were then administered as a bolus (150µmol Fe/kg P904 i.v.) and allowed to 
circulate for two minutes in order to equilibrate before a second set of MGE images were 
acquired. 
This imaging protocol was performed in mice bearing MDA-MB-231 LM2-4 tumors at 
baseline and after 48h treatment with 6mg/kg cediranib, or vehicle, given orally daily 
(additional n=5/group; see supplementary Figure S1). 
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MRI Analysis 
Parameter estimation was undertaken using a Bayesian maximum a posteriori algorithm, 
which took into account the Rician distribution of noise in magnitude MR data in order to 
provide unbiased parameter estimates [26]. Estimates of the apparent diffusion coefficient 
(ADC), a measure of Brownian water diffusion within tissue and surrogate biomarker of 
cellularity and edema, were determined from the DW-MRI data (using 5 b-values; 200-
1000s/mm2). The dual relaxation rate sensitivity of the IR-trueFISP sequence was utilized, 
providing estimates of native T1 and T2 relaxation times. DCE-MRI data were analysed by 
incorporating the Tofts and Kermode pharmacokinetic model, from which the volume 
transfer constant (Ktrans, minute−1), the rate of flux of contrast agent into the extracellular 
extravascular space within a given volume, and a compound biomarker of vascular 
permeability and blood flow, was calculated. In addition, model-free analysis was used to 
derive the initial area under the gadolinium concentration curve at 60 seconds after injection 
(IAUGC60, mmol Gd.minute) [25]. 
Estimates of the MRI transverse relaxation rate R2* were calculated from MGE data. The 
change in R2* following delivery of USPIO (∆R2*) was also evaluated, from which fractional 
blood volume (fBV, %) was estimated [27]. Voxels corresponding to a fBV exceeding 17% 
(the limit value for the linearity between ∆R2* and fBV) were excluded [28]. 
All data were fitted on a pixel-by-pixel basis using in-house software (ImageView, developed 
in IDL, ITT Visual Information Systems, Boulder, CO, USA). The median value of each 
parameter in each tumor was determined and the distribution of data values was assessed. 
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Histological Analysis 
Tumor bearing mice were administered with 15mg/kg of the perfusion marker Hoechst 33342 
(Sigma-Aldrich) intravenously through a lateral tail vein. After 1 minute, animals were killed, 
and whole brains were rapidly excised, snap-frozen and stored in liquid nitrogen [25]. 
Hoechst 33342 fluorescence signals from frozen whole brain sections (10µm, three per 
tumor) were recorded at 365nm using a motorized scanning stage (Prior Scientific 
Instruments, Cambridge, UK) attached to a BX51 microscope (Olympus Optical, London, 
UK), driven by CellP (Soft Imaging System, Münster, Germany). In addition, composite 
images from the tumor region and 40x magnification snapshots of the tumors were acquired.  
The same sections were then processed for the detection of vascular endothelial marker CD31 
(all tumors) and pan cytokeratin (MDA-MB-231 LM2-4 tumors only). Sections were first 
incubated with 2% (w/v) BSA/5% (v/v) goat serum in PBS for 1 hour to block any non-
specific antibody binding, and then with goat anti-mouse CD31 antibodies (MEC 13.3, BD 
Biosciences, Oxford, UK, 1:100) overnight at 4ºC. Sections were washed with 0.1% (v/v) 
Tween-20 in PBS, then incubated with Alexa 546-conjugated goat anti-rat secondary 
antibodies (Invitrogen, 1:500) ± FITC-conjugated mouse monoclonal anti-pan cytokeratin 
antibodies (Clone C-11, Sigma-Aldrich, 1:100) at 37ºC for 4 hours, protected from light. 
Following washing the sections were imaged under PBS. CD31 expression was detected at 
510-560nm and cytokeratin positive tumor cells were detected over the whole brain at 450-
490nm using the same fluorescence microscope system and stage co-ordinates. Composite 
images of the brain, tumor and individual 40x snapshots were recorded, allowing the CD31 
images to be subsequently overlaid on the Hoechst 33342 images. The cytokeratin images 
were used to draw the MDA-MB-231 LM2-4 tumor regions of interest (ROI) used in the 
analysis of the Hoechst 33342 and CD31 data.  
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The sections were then stained with hematoxylin and eosin (H&E), and composite images 
were acquired using the same microscope system and co-ordinates with bright-field 
illumination. These images were used to draw the tumor ROIs used in the analysis of the 
Hoechst 33342 and CD31 data in SF188luc tumors.  
Fluorescent particles were detected above a constant threshold and the area of the tumor 
section with Hoechst 33342 or CD31 fluorescence was determined and expressed as a 
percentage of the whole tumor section. Co-localization of Hoechst 33342 (perfused vessels) 
and CD31 (total vessels) was also assessed and expressed as percentage total vessels perfused 
and a total perfused vessel area.  
 
A separate cohort of mice bearing MDA-MB-231 LM2-4 tumors treated with B20-4.1.1 or 
isotype-matched control antibodies (n=4/group) were administered intravenously with 
50mg/kg Evans blue (Sigma-Aldrich) in PBS. Evans blue readily binds to albumin, and hence 
can be used to visualize and quantify vascular permeability [29, 30]. After 30 minutes 
Hoechst 33342 was administered as described above; 1 minute later the animals were killed, 
and the brains rapidly excised and snap-frozen. Hoechst 33342 and Evans blue fluorescent 
signals were recorded from frozen sections at 365nm and 510-560nm, respectively. Sections 
were then blocked with 2% (w/v) BSA/5% (v/v) goat serum in PBS for 1 hour and incubated 
with FITC-anti-pan cytokeratin antibodies as above. Following washing the sections were 
imaged under PBS. Fluorescent particles were detected above a constant threshold and the 
area of the tumor section with Hoechst 33342 or Evans blue fluorescence was determined and 
expressed as a percentage of the whole tumor section, as determined using cytokeratin 
staining. 
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Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 7 (GraphPad Software, La Jolla, 
USA). The mean of median values for all the quantitative MR imaging parameters, and the 
mean values for tumor volume and the fluorescent area fractions were used for statistical 
analysis. Results are presented as the mean ± 1 standard error of the mean (s.e.m.). 
Significance testing used paired or unpaired Student’s t-tests with a 5% confidence level. 
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Results 
 
Representative anatomical T2-weighted images, and associated parametric ADC and Ktrans 
maps, acquired from mice bearing intracranially implanted SF188luc or MDA-MB-231 LM2-
4 tumors, prior to and following treatment with either cediranib, B20-4.1.1, or the appropriate 
control, are shown in Figures 1, 3 and 5, along with summaries of the quantitative data 
obtained for each tumor model and treatment regimen investigated. Orthotopic SF188luc 
tumors presented as moderately homogeneous hyperintense lesions with relatively well 
defined borders on T2-weighted MRI images (Figure 1a) and were observed to be well 
defined masses with sparse foci of infiltrative cells by H&E staining (supplementary Figure 
S2). Intracranial MDA-MB-231 LM2-4 tumors were more heterogeneous with less well 
defined boundaries on T2-weighted images (Figures 3a and 5a), and H&E staining shows 
partially well circumscribed masses with substantial local invasion, principally occurring 
along blood vessels, with evidence of edema (supplementary Figure S2) [16, 24]. 
Treatment of mice bearing orthotopic SF188luc pediatric glioblastomas with cediranib 
significantly inhibited tumor progression compared with vehicle-treated controls (p<0.01, 
Figure 1a&b). Tumor ADC was not significantly altered over 48 hours in either treatment 
group (Figure 1b). In the cediranib-treated SF188luc cohort DCE-MRI consistently showed a 
marked reduction in contrast agent uptake after treatment, resulting in non-significant 53%  
and 59% reductions in Ktrans (Figure 1b) and IAUGC60 (data not shown), respectively. The 
mean post-treatment Ktrans was significantly lower in the cediranib-treated cohort than in the 
vehicle-treated controls (p<0.05). Frequency histograms of individual voxel ADC and Ktrans 
values in five equally sized bins were also used to evaluate any treatment-induced changes in 
data distribution (Figure 1c). Differences in the distribution of Ktrans values prior to and 
following treatment with cediranib were apparent, including a marked increase in the 
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proportion of voxels with values of 0-0.02min-1 and a significant reduction in values of 0.02-
0.04min-1 (p<0.05). Histological assessment of Hoechst 33342 perfused area, CD31 positive 
total vessel area, and their co-localization in SF188luc tumors treated with either vehicle or 
cediranib revealed no significant difference in vascular perfusion, total vascular area or the 
percentage of vessels perfused at the time of Hoechst 33342 injection between treatment 
groups (Figure 2). 
Treatment of intracranially-implanted MDA-MB-231 LM2-4 tumors with cediranib resulted 
in significant growth delay compared with vehicle-treated controls (p<0.05, Figure 3a&b). 
This response was associated with a statistically significant 9% reduction in ADC in the 
cediranib-treated cohort (p<0.05), accompanied by significant 49% and 52% decreases in 
Ktrans (Figure 3b) and IAUGC60 (data not shown), respectively (p<0.05). There was no 
significant change in DW- or DCE-MRI parameters over 48h in the vehicle-treated cohort. 
Frequency histograms showed that the reduction in ADC following cediranib treatment was 
associated with a decrease in the proportion of voxels with values of 900-1200x10-6mm2s-1 
(p<0.05) and 1200-1500x10-6mm2s-1 (p=0.08), and increases in the number of voxels in the 
300-600 and 600-900x10-6mm2s-1 bins (p=0.08) (Figure 3c). The reduction in Ktrans in the 
cediranib-treated tumors was associated with a non-significant increase in the proportion of 
voxel values of 0-0.2min-1 and reductions in the size in all other bins.  Histological 
assessment of Hoechst 33342 uptake demonstrated that cediranib-treated MDA-MB-231 
LM2-4 tumors were significantly less well perfused than vehicle-treated tumors (p<0.05, 
Figure 4). CD31 positive total vessel area was also lower in the treated tumors, but the 
difference did not reach statistical significance (p=0.052). Assessment of the co-localization 
of Hoechst 33342 and CD31 revealed that the percentage of vessels perfused at the time of 
Hoechst 33342 injection was significantly lower in the cediranib-treated cohort (p<0.05). 
Susceptibility contrast MRI revealed no significant treatment-induced change in the fractional 
17 
 
blood volume (fBV) of the MDA-MB-231 LM2-4 tumors (pre vehicle 5.0±0.4%, 48h vehicle 
4.7±0.1%; pre cediranib 5.1±0.3%, 48h cediranib 5.1±0.4%). 
Treatment with a single dose of B20-4.1.1 significantly inhibited the growth of intracranial 
MDA-MB-231 LM2-4 tumors over 48 hours compared with controls (p<0.01, Figure 5a&b). 
There was no significant change in ADC in the B20-4.1.1-treated tumors but growth 
inhibition was associated with significant 41% and 53% reductions in Ktrans (Figure 5b) and 
IAUGC60 (data not shown), respectively (p<0.05). No quantitative MRI parameters changed 
over 48 hours in the control tumors. Despite there being no significant change in overall 
tumor ADC in response to B20-4.1.1, a change in the distribution of the data was apparent, 
with a significant reduction in the proportion of voxels with ADC values of 900-1200x10-
6mm2sec-1 and a significant increase in voxels with values of 300-600x10-6mm2sec-1 (both 
p<0.05). The reduction in Ktrans in the B20-4.1.1-treated cohort was attributable to a 
significant increase in the number of voxels with a value of 0-0.02min-1 and significant 
reductions the proportion of voxels with values between 0.2-0.4min-1 and 0.4-0.6min-1 (all 
p<0.05, Figure 5c). Histological assessment of Hoechst 33342 uptake, CD31 expression and 
their co-localization in MDA-MB-231 LM2-4 tumors treated with either B20-4.1.1 or control 
antibodies revealed no difference in vascular perfusion (Figure 6), total vascular area or the 
percentage of perfused vessels between treatment groups (data not shown). A markedly lower 
uptake and distribution of the permeability marker Evans Blue was apparent in the B20-4.1.1-
treated tumors compared with the control cohort (B20-4.1.1 22±5%, control 34±2%, 
p=0.068).  
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Discussion 
 
In this study multiparametric MRI was used to assess the response of intracranial tumors to 
drugs targeting the VEGF/VEGFR pathway. Specifically, the efficacy of the pan-VEGFR 
small molecule inhibitor cediranib in orthotopic SF188luc pediatric glioblastoma xenografts 
and intracranial MDA-MB-231 LM2-4 TNBC xenografts was assessed alongside the 
response of MDA-MB-231 LM2-4 tumors to the human/mouse cross-reactive anti-VEGF-A 
monoclonal antibody B20-4.1.1. Anatomical T2-weighted MRI and functional DW- and 
DCE-MRI were used to assess any treatment-induced changes in tumor progression, 
cellularity and edema, and vascular permeability/perfusion, respectively. An acute time point 
of 48h was chosen because early imaging changes have been detected in glioblastoma, breast 
cancer and other solid tumors, including extracranial breast cancer metastases, following 
cediranib, bevacizumab and axitinib treatment [15, 31, 32]. In addition, response to 
bevacizumab at just 96h, as well as 4 weeks, was predictive of improved PFS in recurrent 
glioma [33]. 
Treatment of orthotopic SF188luc pediatric glioblastoma xenografts with cediranib resulted in 
significant growth delay over 48 hours. DW-MRI revealed no significant change in water 
diffusivity following treatment with cediranib in SF188luc tumors; these tumors were densely 
cellular and there was no edema present (supplementary Figure S2), exemplified by baseline 
ADC values being considerably lower in SF188luc than MDA-MB-231 LM2-4 tumors (mean 
pre-treatment ADC; SF188luc 621x10-6mm2s-1, MDA-MB-231 LM2-4 827x10-6mm2s-1). 
Paired comparisons of mean DCE-MRI data acquired from the same tumors prior to and post 
treatment did not reveal any significant anti-vascular effect. However, assessment of the 
distribution of Ktrans values revealed a shift towards lower values in the treated tumors. The 
lack of an overall significant response is likely a consequence of the wide dynamic range of 
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pre-treatment Ktrans values measured in the cediranib-treated group. The average post-
treatment Ktrans was, however, significantly lower in the cohort treated with cediranib 
compared with the vehicle-treated tumors, suggestive of an anti-vascular effect. 
Adult patients with glioblastoma treated with bevacizumab, alone or in combination with 
chemotherapy (most commonly irinotecan), have demonstrated reductions in MRI contrast 
enhancement and vasogenic edema resulting in significant improvements in progression-free 
survival [15, 34]. Bevacizumab in combination with radiotherapy and temozolomide has also 
been shown to extend progression free survival in newly diagnosed glioblastoma [35, 36]. A 
phase I clinical trial assessing cediranib as a single agent in children with recurrent and 
refractory primary central nervous system tumors has recently been completed, in which 
decreased diffusivity and perfusion were observed in responding tumours [37]. The efficacy 
of bevacizumab in combination with chemotherapy or radiotherapy is currently being 
assessed in the same patient population [38], with functional MRI included in at least one 
such trial [19].   
Growth of intracranial MDA-MB-231 LM2-4 tumors was significantly suppressed over the 
duration of 48 hours treatment with cediranib. The sensitivity of the parental MDA-MB-231 
cell line to cediranib has previously been shown in vitro and in vivo in subcutaneous 
xenografts [5]. Here, cediranib-induced growth delay in intracranial MDA-MB-231 LM2-4 
tumors was associated with significant reductions in both Ktrans, measured in vivo by DCE-
MRI, and perfused vessel area assessed histologically. Interestingly, susceptibility contrast 
MRI using an intravascular USPIO particle-based contrast agent revealed no significant 
difference in tumor fractional blood volume (fBV) in response to cediranib. Contrary to 
gadolinium-chelated contrast agents such as Magnevist, high molecular weight USPIO 
particles do not leak as readily from the blood vessels, hence quantitation of fBV represents 
an imaging biomarker of more patent vasculature. The differential response of Ktrans and fBV 
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observed herein therefore suggests that cediranib is targeting permeable neovasculature in the 
intracranial MDA-MB-231 LM2-4 tumors. Indeed, previous studies of anti-VEGF 
therapeutics have shown that the reduction in Ktrans is associated with pruning of immature 
vessels [15]. Treatment with cediranib also elicited a significant reduction in tumor ADC, 
consistent with the resolution of edema following pruning of hyperpermeable vessels and the 
resulting reduction in fluid extravasation; which has been observed in both preclinical models 
of glioblastoma and patients with brain tumors [15, 39]. The reduction in edema, and 
therefore intracranial pressure, is thought to have a significant role in increased survival 
following VEGF blockade [15, 39].  
Cediranib is primarily a potent pan-VEGFR inhibitor, but at the dose used in this study also 
elicits marked activity against c-kit and platelet-derived growth factor receptor (PDGFR)-α 
and -β [40], whose inhibition may also contribute to the anti-tumor and anti-vascular effects 
observed. Amplification of PDGFRA, and less commonly PDGFRB, is observed in pediatric 
high grade glioma [41-43], indeed SF188luc cells overexpress PDGFRβ [44]. Overexpression 
of PDGFRα is also an adverse prognostic factor in advanced breast cancer [45, 46].  
MDA-MB-231 LM2-4 tumors were also treated with B20-4.1.1, a cross-reactive 
human/mouse anti-VEGF-A monoclonal antibody, that allows the simultaneous targeting of 
VEGF-A produced by human-derived tumor cells and mouse-derived stromal cells. Whilst 
the relative contributions of tumor- and stroma- derived VEGF-A differ between in vivo 
tumor models [47], targeting both recapitulates patient response more accurately than 
targeting tumor-derived VEGF alone. Similar to the response following treatment with 
cediranib, B20-4.1.1 elicited significant growth delay in MDA-MB-231 LM2-4 tumors 
relative to isotype-matched antibody-treated mice. Treatment with B20-4.1.1 also resulted in 
a significant reduction in Ktrans. This was however not associated with a reduction in Hoechst 
33342 perfusion, total CD31 positive vessel area or percentage of vessels perfused, 
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suggesting that the change in Ktrans may predominantly reflect a reduction in vascular 
permeability. The uptake of Evans blue, an azo dye with high affinity for albumin used to 
assess the degree of tumor vascular permeability, and unable to pass through the blood brain 
barrier, was lower in B20.4.1.1-treated tumors, but values did not reach statistical 
significance. Whilst the mean of individual tumor median ADC values did not change in 
response to treatment with B20-4.1.1, a change in the distribution of the data, with a shift 
towards lower values, was observed, suggesting some alteration in the degree of water 
diffusion with the tumors post treatment, again possibly as a result of resolution of edema.  
The imaging response of intracranial MDA-MB-231 LM2-4 tumors to VEGF/VEGFR 
pathway inhibitors with differing mechanisms of action are subtly different, with perfused 
vessel area and degree of water diffusion not significantly changing in response to B20-4.1.1, 
but being altered by cediranib treatment.  
In a recent phase II study, patients with parenchymal brain breast metastases who responded 
to bevacizumab in combination with carboplatin demonstrated improved cerebral blood flow, 
pruning of macroscopic vessels and increased oxygen saturation as a result of vascular 
normalization [48]. Reduced tumor vessel perfusion/permeability has also been observed 
following bevacizumab treatment in previously untreated patients with inflammatory or 
locally advanced breast cancer [31].  
SF188luc tumors grow as well defined masses with sparse foci of infiltrative cells, therefore 
not accurately modelling the heterogeneity of pHGG growth with infiltrative regions, 
however these tumors model the angiogenic component of the tumors that VEGF pathway 
inhibition targets. Similarly, whilst intracranial implantation of MDA-MB-231 LM2-4 cells 
does not strictly model brain breast cancer metastasis, these tumors grow as partially well 
circumscribed, partially invasive, tumors with lower vascular permeability in invasive regions 
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[16] and provide a reproducible model of intracranial tumor growth in which to perform 
imaging investigations. 
The vascular and diffusion parameters reported herein did not change in any control cohort, 
all of which exhibited a larger change in volume over 48h than the treated tumors, 
demonstrating that these biomarkers are not affected by tumor volume over this size range. 
DCE-MRI-derived estimates of Ktrans using a low molecular weight gadolinium-chelated 
contrast agents represents a compound biomarker of both tumor perfusion and permeability 
[49], and changes in Ktrans in response to vascular-targeted therapies can be challenging to 
correctly interpret [50]; VEGF pathway blockade has been shown to partially restore the 
compromised blood brain barrier in human glioblastomas resulting in reduced tumor 
detectability by Gd-DTPA enhanced MRI [51].  In DCE-MRI studies of human brain tumors, 
Ktrans is often reported as a measure of permeability alone, due to the high flow rate and low 
permeability of brain blood vessels [52]. Alternative imaging strategies are therefore 
continually being evaluated for the assessment of brain tumor perfusion and its response in 
vivo [53, 54]. Dynamic susceptibility MRI, acquired during the first circulatory pass of Gd-
DTPA, can provide a measure of cerebral blood flow (CBF, ml/100g/min), which has been 
reported to decrease in response to cediranib in glioma patients [15].  
We show here that in preclinical models of pediatric glioblastoma and breast cancer brain 
metastases VEGF pathway blockade resulted in tumor growth retardation and inhibition of 
tumor vasculature. These data suggest that antiangiogenic therapy, alone or in combination, 
may be beneficial and is worth pursuing in patients with brain metastases and in pediatric 
brain tumor patients, both of which are patient populations with limited therapeutic options. 
The use of multiparametric MRI to monitor such regimens may also inform on expedient 
therapy switching in the event of poor response and may provide a powerful adjunct to 
23 
 
accelerate the development of new antiangiogenic therapies for use in these patient 
populations. 
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Figure Legends 
 
Figure 1. Anatomical, diffusion-weighted and dynamic contrast-enhanced MRI of 
orthotopic SF188luc tumors treated with cediranib. 
a) T2-weighted MRI images, and associated parametric apparent diffusion coefficient (ADC) 
and Ktrans maps, from representative orthotopic SF188luc pediatric glioblastomas prior to and 
following 48 hours treatment with either vehicle or cediranib, as indicated. b) Quantification 
of the change in tumor volume over the 48h treatment period, and of ADC and Ktrans prior to, 
and following, treatment with vehicle (n=5) or cediranib (n=6). c) Frequency distributions of 
all tumor ADC and Ktrans voxels. Distributions were divided into 5 equally sized bins for each 
dataset, using 0-300, 300-600, 600-900, 900-1200, 1200-1500x10-6mm2sec-1 for ADC and 0-
02, 0.2-0.4, 0.4-0.6, 0.6-0.8, 0.8-0.1min-1 for Ktrans. ##p<0.01, #p<0.05, unpaired Student’s t-
test between vehicle and cediranib-treated cohorts. *p<0.05, paired Student’s t-test. 
 
Figure 2. Histological assessment of perfusion and vascular density in orthotopic 
SF188luc tumors in response to cediranib. 
a) Representative fluorescence images of the uptake of the perfusion marker Hoechst 33342 
(blue), and immunohistochemical detection of the vascular endothelial marker CD31 (red), 
acquired from whole brain sections from mice bearing orthotopic SF188luc tumors treated 
with vehicle or cediranib. Composite Hoechst 33342 and CD31 images acquired at 40x 
magnification are also shown, demonstrating both co-localisation and mismatch of the 
vascular markers. Tumor ROIs are shown in green, T denotes tumor region on the composite 
images. b) Quantification of Hoechst 33342 perfused area, CD31 positive vessel area, and the 
percentage of vessels perfused. Three sections per tumor were assessed and the mean for each 
tumor is represented. 
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Figure 3. Anatomical, diffusion-weighted and dynamic contrast-enhanced MRI of 
intracranial MDA-MB-231 LM2-4 tumors treated with cediranib. 
a) T2-weighted MRI images, and associated parametric ADC and Ktrans maps, from 
representative intracranial MDA-MB-231 LM2-4 tumors prior to, and following, 48 hours 
treatment with either vehicle or 6mg/kg cediranib daily, as indicated. b) Quantification of the 
change in tumor volume over the 48h treatment period, and of ADC and Ktrans prior to, and 
following, treatment with either vehicle (n=5) or cediranib (n=6). c) Frequency distributions 
of all tumor ADC and Ktrans voxels. Distributions were divided into 5 equally sized bins for 
each dataset, using 0-300, 300-600, 600-900, 900-1200, 1200-1500x10-6mm2sec-1 for ADC 
and 0-02, 0.2-0.4, 0.4-0.6, 0.6-0.8, 0.8-0.1min-1 for Ktrans. #p<0.05, unpaired Student’s t-test 
between vehicle and cediranib-treated cohorts. *p<0.05, paired Student’s t-test.  
 
Figure 4. Histological assessment of perfusion and vascular density in intracranial 
MDA-MB-231 LM2-4 tumors in response to cediranib. 
a) Representative fluorescence images of the uptake of the perfusion marker Hoechst 33342 
(blue), and immunohistochemical detection of the vascular endothelial marker CD31 (red), 
acquired from whole brain sections from mice bearing intracranial MDA-MB-231 LM2-4 
tumors treated with vehicle or cediranib. Composite Hoechst 33342 and CD31 images 
acquired at 40x magnification are also shown, demonstrating both co-localisation and 
mismatch of the vascular markers. Tumor ROIs are shown in green, T denotes tumor region 
on the composite images. b) Quantification of Hoechst 33342 perfused area, CD31 positive 
vessel area, and the percentage of vessels perfused. Three sections per tumor were assessed 
and the mean for each tumor is represented. #p<0.05, unpaired Student’s t-test. 
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Figure 5. Anatomical, diffusion-weighted and dynamic contrast-enhanced MRI of 
intracranial MDA-MB-231 LM2-4 tumors treated with B20-4.1.1. 
a) T2-weighted MRI images, and associated parametric ADC and Ktrans maps, from 
representative intracranial MDA-MB-231 LM2-4 tumors prior to and 48 hours after a single 
10mg/kg dose of isotype-matched control antibody Ragweed:1428 (control) or B20-4.1.1, as 
indicated. b) Quantification of the change in tumor volume over the 48h treatment period, 
and of Ktrans and ADC, prior to, and following, treatment with control antibody (n=6) or B20-
4.1.1 (n=7). c) Frequency distributions of all tumor ADC and Ktrans voxels. Distributions were 
divided into 5 equally sized bins for each dataset, using 0-300, 300-600, 600-900, 900-1200, 
1200-1500x10-6mm2sec-1 for ADC and 0-02, 0.2-0.4, 0.4-0.6, 0.6-0.8, 0.8-0.1min-1 for Ktrans. 
##p<0.01, unpaired Student’s t-test between control and B20-4.1.1-treated cohorts; *p<0.05, 
paired Student’s t-test.  
 
Figure 6. Histological assessment of vascular perfusion and permeability in intracranial 
MDA-MB-231 LM2-4 tumors in response to B20-4.1.1. 
a) Representative fluorescence images of the uptake of the perfusion marker Hoechst 33342 
(blue), and the permeability marker Evans blue (red), acquired from brain sections taken from 
mice bearing intracranial MDA-MB-231 LM2-4 tumors treated with either isotype-matched 
control antibody Ragweed:1428 (control, n=4) or B20-4.1.1 (n=4). Tumor ROIs are shown in 
green. b) Quantification of Hoechst 33342 perfused area and Evans blue positive area. Three 
sections per tumor were assessed and the mean for each tumor is represented.  
 
Supplementary Figure S1. Schematic of experimental design 
Tumor-bearing animals were randomized into experimental groups when bioluminescence 
signal reached a level representing a tumor volume of ~25mm3. Mean days after implantation 
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at study start and mean tumor volume (derived from pre-treatment T2-weighted MRI) ± s.e.m. 
are shown for each cohort. 6mg/kg cediranib or equivalent volume of vehicle was given 
daily; a single 10mg/kg dose of B20-4.1.1 or isotype control Ragweed:1428 was given. 
MRI protocols used diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI or 
susceptibility-contrast (SC) MRI. 
 
Supplementary Figure S2. Hematoxylin and eosin staining of intracranial SF188luc and 
MDA-MB-231 LM2-4 tumors. 
Representative hematoxylin and eosin (H&E) stained 5µm thick formalin-fixed paraffin-
embedded (FFPE) brain sections from untreated mice bearing SF188luc or MDA-MB-231 
LM2-4 tumors; lower panel x200 magnification. Note the dense cellularity and minimal 
invasion in the SF188luc tumor, and the invasion associated with the blood vessels (open head 
arrow) and edema (closed head arrow) present in the MDA-MB-231 LM2-4 tumor. 
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